CD133 Expression is an Independent Prognostic Marker for Low Survival in Colorectal Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2008 Sep 11

PMID 18781171

Citations 142

Authors

D Horst

L Kriegl

J Engel

T Kirchner

A Jung

Affiliations

Soon will be listed here.

Abstract

Colon cancer cells have previously been demonstrated to contain a subpopulation of CD133+ tumour cells that have the ability to initiate tumour growth and are thus referred to as colon cancer-initiating cells or colon cancer stem cells (CSCs). As CD133 is currently one of the best markers to characterise colon CSCs, we analysed CD133+ tumour cells in colorectal cancer specimens using immunohistochemistry. We show that CD133 detection is specific and that the CD133 antigen is localised on the glandular-luminal surface of colon cancer cells, whereas undifferentiated tumour cells at the front of invasion are CD133-. In addition, CD133+ cells are characterised in situ by lack of CK20 expression, whereas they are positive for EpCAM. Moreover, we show that CD133 expression in colorectal cancer is an independent prognostic marker that correlates with low survival in a stratified patient collective. Our results indicate that in colorectal cancer, the CD133+ tumour cells can be detected by immunohistochemistry, which facilitates their further characterisation in situ.

Citing Articles

Oncogenic Mutations and the Tumor Microenvironment: Drivers of Non-Small Cell Lung Cancer Progression.

Mitrakas A, Kakouratos C, Lamprou I, Xanthopoulou E, Koukourakis M Cancers (Basel). 2025; 17(5).

PMID: 40075700 PMC: 11899603. DOI: 10.3390/cancers17050853.

Meta-Analysis of Prognostic Significance of Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma.

Tripathi A, Singh M, Mishra P, Fatima N, Kumar V Asian Pac J Cancer Prev. 2024; 25(10):3597-3607.

PMID: 39471027 PMC: 11711375. DOI: 10.31557/APJCP.2024.25.10.3597.

Proinflammatory Microenvironment in Adenocarcinoma Tissue of Colorectal Carcinoma.

Todorovic S, Ceranic M, Toskovic B, Diklic M, Ajtic O, Suboticki T Int J Mol Sci. 2024; 25(18).

PMID: 39337548 PMC: 11432548. DOI: 10.3390/ijms251810062.

CD133-containing microvesicles promote colorectal cancer progression by inducing tumor angiogenesis.

Kim B, Kim S, Park S, Ko J Heliyon. 2024; 10(7):e29292.

PMID: 38601650 PMC: 11004418. DOI: 10.1016/j.heliyon.2024.e29292.

Advances in Translational Nanotechnology: Challenges and Opportunities.

Mohapatra S, Frisina R, Mohapatra S, Sneed K, Markoutsa E, Wang T Appl Sci (Basel). 2024; 10(14).

PMID: 38486792 PMC: 10938472. DOI: 10.3390/app10144881.

References

Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M . CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer. 2008; 98(8):1389-97. PMC: 2361715. DOI: 10.1038/sj.bjc.6604307. View

Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt S . The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem. 2000; 275(8):5512-20. DOI: 10.1074/jbc.275.8.5512. View

Miraglia S, Godfrey W, Yin A, Atkins K, Warnke R, HOLDEN J . A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 1998; 90(12):5013-21. View

Ueno H, Murphy J, Jass J, Mochizuki H, Talbot I . Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002; 40(2):127-32. DOI: 10.1046/j.1365-2559.2002.01324.x. View

Hase K, Shatney C, Johnson D, Trollope M, Vierra M . Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum. 1993; 36(7):627-35. DOI: 10.1007/BF02238588. View

Hermann P, Huber S, Herrler T, Aicher A, Ellwart J, Guba M . Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2008; 1(3):313-23. DOI: 10.1016/j.stem.2007.06.002. View

Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T . Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005; 5(9):744-9. DOI: 10.1038/nrc1694. View

Reya T, Morrison S, Clarke M, Weissman I . Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-11. DOI: 10.1038/35102167. View

OBrien C, Pollett A, Gallinger S, Dick J . A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2006; 445(7123):106-10. DOI: 10.1038/nature05372. View

10.

Mizrak D, Brittan M, Alison M . CD133: molecule of the moment. J Pathol. 2007; 214(1):3-9. DOI: 10.1002/path.2283. View

11.

Todaro M, Perez Alea M, Di Stefano A, Cammareri P, Vermeulen L, Iovino F . Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2008; 1(4):389-402. DOI: 10.1016/j.stem.2007.08.001. View

12.

Dalerba P, Dylla S, Park I, Liu R, Wang X, Cho R . Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007; 104(24):10158-63. PMC: 1891215. DOI: 10.1073/pnas.0703478104. View

13.

Burkert J, Wright N, Alison M . Stem cells and cancer: an intimate relationship. J Pathol. 2006; 209(3):287-97. DOI: 10.1002/path.2016. View

14.

Ricci-Vitiani L, Pagliuca A, Palio E, Zeuner A, De Maria R . Colon cancer stem cells. Gut. 2008; 57(4):538-48. DOI: 10.1136/gut.2007.127837. View

15.

Ricci-Vitiani L, Lombardi D, Pilozzi E, Biffoni M, Todaro M, Peschle C . Identification and expansion of human colon-cancer-initiating cells. Nature. 2006; 445(7123):111-5. DOI: 10.1038/nature05384. View